Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,036 | -9,566 | -37,340 | -29,204 | -19,937 |
| Accounts payable and accrued liabilities | 747 | 1,806 | 2,301 | 983 | 377 |
| Other Working Capital | -4,493 | -1,809 | 3,345 | 659 | -1,051 |
| Other Operating Activity | 339 | -1,192 | 284 | 977 | 918 |
| Operating Cash Flow | $-20,443 | $-10,761 | $-31,410 | $-26,585 | $-19,693 |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | N/A | N/A | -5,500 | -5,500 | -2,500 |
| Other Investing Activity | 0 | 0 | -5,500 | -5,500 | -2,500 |
| Investing Cash Flow | $N/A | $N/A | $-5,500 | $-5,500 | $-2,500 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 27,060 | 26,646 | 22,346 | 18,929 | 18,875 |
| Other Financing Activity | 0 | 0 | -31 | 0 | 0 |
| Financing Cash Flow | $27,060 | $26,646 | $22,315 | $18,929 | $18,875 |
| Beginning Cash Position | 2,630 | 2,630 | 17,225 | 17,225 | 17,225 |
| End Cash Position | 9,247 | 18,515 | 2,630 | 4,069 | 13,907 |
| Net Cash Flow | $6,617 | $15,885 | $-14,595 | $-13,156 | $-3,318 |
| Free Cash Flow | |||||
| Operating Cash Flow | -20,443 | -10,761 | -31,410 | -26,585 | -19,693 |
| Free Cash Flow | -20,443 | -10,761 | -31,410 | -26,585 | -19,693 |